Nimodipine is a Ca2 channel blocker that inhibits smooth muscle contraction by preventing Ca2 from entering cells, thereby relieving vasospasm. It has a strong effect on cerebral arteries and easily penetrates the blood-brain barrier. It can be used to prevent vasospasm after subarachnoid hemorrhage. It also has the effect of protecting and promoting memory.

This product can directly penetrate the cell membrane into the body cells, activate pyruvate oxidase, so that cells in a low-energy and hypoxic state can continue to metabolize smoothly, and participate in the energy metabolism and protein synthesis of the human body.

This product belongs to Class Ib antiarrhythmic drugs, inhibits the permeability of cell membrane to Na, but does not promote K outflow. It can slow down the conduction of various parts of the cardiac conduction system, reduce membrane reactivity, increase the excitation threshold, prolong the effective adaptation period of the atrium, atrioventricular node, His-Purkinje system (Purkinjes fibers) and ventricle, and block the forward and reverse conduction of the bypass pathway.

It is a selective beta-1 adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.